



**HAL**  
open science

## Characteristics and progression of patients with frontotemporal dementia in a regional memory clinic network

Mélanie Leroy, Maxime Bertoux, Emilie Skrobala, Elisa Mode, Catherine Adnet-Bonte, Isabelle Le Ber, Stéphanie Bombois, Pascaline Cassagnaud, Yaohua Chen, Vincent Deramecourt, et al.

### ► To cite this version:

Mélanie Leroy, Maxime Bertoux, Emilie Skrobala, Elisa Mode, Catherine Adnet-Bonte, et al.. Characteristics and progression of patients with frontotemporal dementia in a regional memory clinic network. *Alzheimer's Research and Therapy*, 2021, 13, pp.19. 10.1186/s13195-020-00753-9 . hal-03048105

**HAL Id: hal-03048105**

**<https://hal.science/hal-03048105>**

Submitted on 9 Dec 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

[Click here to view linked References](#)

# Characteristics and progression of patients with frontotemporal dementia in a regional memory clinic network

## **Author names and affiliations**

Mélanie Leroy<sup>1</sup>, Maxime Bertoux<sup>1</sup>, Emilie Skrobala<sup>2</sup>, Elisa Mode<sup>3</sup>, Catherine Adnet-Bonte<sup>1</sup>, Isabelle Le Ber<sup>4</sup>, Stéphanie Bombois<sup>1</sup>, Pascaline Cassagnaud<sup>1</sup>, Yaohua Chen<sup>1</sup>, Vincent Deramecourt<sup>1</sup>, Florence Lebert<sup>1</sup>, Marie Anne Mackowiak<sup>1</sup>, Adeline Rollin Sillaire<sup>1</sup>, Marielle Wathelet<sup>4</sup>, Florence Pasquier<sup>1</sup>, Thibaud Lebouvier<sup>1</sup> and the Méotis network<sup>5</sup>

1. Univ. Lille, Inserm, CHU-Lille, Lille Neuroscience & Cognition, CNRMAJ, LICEND, F-59000 Lille, France
2. CHU Lille, DISTALZ, Lille, France
3. Univ. Lille, Inserm, CHU-Lille, F-59000 Lille, France
4. Sorbonne Université, Inserm U1127, CNRS UMR 7225, Institut du Cerveau (ICM), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France and Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France.
5. Department of Public Health, CHU Lille, F-59000 Lille, France
6. See appendix A

Corresponding author: Dr Thibaud Lebouvier [thibaud.lebouvier@chru-lille.fr](mailto:thibaud.lebouvier@chru-lille.fr)

## **Keywords**

Frontotemporal dementia, epidemiology, progression, dementia

## **Abbreviations**

1  
2 AD: Alzheimer's disease

3  
4  
5 AChEIs: AcetylCholinEsterase Inhibitors

6  
7 ANOVA: ANalysis Of VAriance

8  
9  
10 bvFTD: Behavioural variant of frontotemporal dementia

11  
12 C9ORF72: chromosome 9 open reading frame 72

13  
14  
15 CBD: Corticobasal degeneration

16  
17 CBS: Corticobasal syndrome

18  
19  
20 CSF: Cerebrospinal fluid

21  
22  
23 FTD: Frontotemporal dementia

24  
25 IADL: Instrumental Activities of Daily Living

26  
27  
28 MAPT: Microtubule-associated protein tau

29  
30 MC: Memory Clinic

31  
32  
33 mFTD: Frontotemporal lobar degeneration with primarily motor symptoms

34  
35  
36 MMSE: Mini mental state examination

37  
38  
39 MRRC: Memory Resources and Research Center

40  
41  
42 lvFTD: Language variants of frontotemporal lobar degeneration

43  
44  
45 PPA: primary progressive aphasia

46  
47  
48 PGRN: Progranuline

49  
50  
51 PSP: Progressive supranuclear palsy

52  
53  
54 TDP-43: TAR DNA binding protein 43

## **Appendix A**

1  
2 The MEOTIS network. Dr ABIED Rachid, Dr ADNET Cathrine, Dr BAROIS Arnaud, Dr BAUDE  
3 Stéphanie, Dr BERRIOT Véronique, Dr BOMBOIS Stéphanie, Dr BOYER Gloria, Dr BRIQUE Didier, Dr  
4 CALAIS Gauthier, Dr CASSAGNAUD Pascaline, Dr CHEKROUD Hacène, Dr CHEN Yaohua, Dr  
5 CLICHE Joel, Dr CRINQUETTE Charlotte, Dr DACHY Valérie, Dr DEBOCK Valerie, Dr  
6 DEPRez Anne, Pr DERAMECOURT Vincent, Dr DEREPPER Olivier, Dr DEVOS Philippe, Dr  
7 ELAZOUZI Abdelghani, Dr ENDERLE Adeline, Dr FANJAUD Nicolas, Dr FORZY Pierre, Dr GALLOUJ  
8 Karim, Dr GARCON Karine, Dr HONORE Marie, Dr HUVENT Dominique, Dr IDIRI Houria, Dr LADEIRO  
9 Annabelle, Dr LAVENU Isabelle, Dr LEBERT Florence, Dr LEBOUVIER Thibaud, Dr LE COZ Patrick,  
10 Dr LECLERCQ Eugénie, Dr LEFEBVRE Denis, Dr MACIEJASZ Pierre, Dr MACKOWIAK Marie-Anne,  
11 Dr MESSIN Rémi, Pr PASQUIER Florence, Dr PETIT Valérie, PLICHON Christine, Dr PONTHEU  
12 Sandrine, Dr QUIEVRE Cécile, Dr ROCHE Jean, Dr ROLLIN SILLAIRE Adeline, Dr ROSOLACCI  
13 Thierry, Dr SENECHAL Olivier, Dr TAILLEZ Nathalie, Dr THIBAUT TANCHOU Stéphanie, Dr TISON  
14 Frédéric, Dr TOLLOT Sarah, Dr TROCMET Marie, Dr VERPOORT Charlotte  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

# Abstract

## *Background*

Due to heterogeneous clinical presentation, difficult differential diagnosis with Alzheimer's disease (AD) and psychiatric disorders, and evolving clinical criteria, the epidemiology and natural history of frontotemporal lobar degeneration (FTD) remain elusive. In order to better characterize FTD patients we relied on the database of a regional memory clinic network with standardized diagnostic procedures and chose AD patients as a comparator.

## *Methods*

Patients that were first referred to our network between January 2010 and December 2016 and whose last clinical diagnosis was degenerative or vascular dementia were included. Comparisons were conducted between FTD and AD as well as between the different FTD syndromes, divided into language variants (lvFTD), behavioral variant (bvFTD) and FTD with primarily motor symptoms (mFTD). Cognitive progression was estimated with the yearly decline in Mini Mental State Examination (MMSE).

## *Results*

Among the patients that were referred to our network in the six-year time span, 690 were ultimately diagnosed with FTD and 18,831 with AD. Patients with FTD syndromes represented 2.6% of all-cause dementias. The age-standardized incidence was 2.90 per 100 000 person-year and incidence peaked between 75 and 79 years. Compared to AD, patients with FTD syndromes had a longer referral delay and delay to diagnosis. Patients with FTD syndromes had a higher MMSE score than AD at first referral while their progression was similar. mFTD patients had the shortest survival while survival in bvFTD, lvFTD and AD did not significantly differ. **FTD patients, especially those with the behavioral variant, received more antidepressants, anxiolytics and antipsychotics than AD patients.**

## *Conclusions*

FTD syndromes differ with AD in characteristics at baseline, progression rate and treatment. Despite a broad use of the new diagnostic criteria in an organized memory clinic network, FTD syndromes are longer to diagnose and account for a low proportion of dementia cases, suggesting persistent underdiagnosis. Congruent with recent publications, the late peak of incidence warns against considering FTD as being exclusively a young-onset dementia.

# Background

1  
2  
3  
4 Frontotemporal lobar degeneration (FTD) is the second leading cause of early-onset dementia after  
5  
6 Alzheimer’s disease (AD) [1]. FTD is characterized by changes in behaviour and/or language due to the  
7  
8 relatively selective atrophy of the frontal and temporal lobes [2]. In the past decade, the nosology of FTD  
9  
10 has evolved outstandingly, prompting changes in diagnostic criteria. There are three main clinical  
11  
12 presentations of FTD. The behavioural variant of FTD (bvFTD) is defined by an early and prominent  
13  
14 behavioural and dysexecutive syndrome, whose core symptoms were revised by Rascovsky et al. in  
15  
16 2011 [3]. The two language variants of FTD (lvFTD) include the semantic and non-fluent presentations  
17  
18 of primary progressive aphasia (PPA), also defined by updated clinical criteria [4]. In addition, FTD can  
19  
20 initially present with motor symptoms (mFTD) such as features of atypical parkinsonism (progressive  
21  
22 supranuclear palsy [PSP] and corticobasal syndrome [CBS]) [5].  
23

24  
25 Although being an umbrella term underlain by >20 different possible pathologies [6], FTD stands as a  
26  
27 unifying entity because of the lack of correlations between FTD syndromes and pathology [7]. bvFTD,  
28  
29 for example, can be underlain by tau, TDP-43 or rarer pathologies, and on the contrary, one single  
30  
31 pathology, such as PSP, can manifest with several clinical syndromes [6]. One exception to the  
32  
33 unpredictability of the underlying pathology is the identification of a causal genetic mutation. Patients  
34  
35 with FTD syndromes have a positive family history in 26-31% [8], highlighting the importance of genetics.  
36  
37 The most common FTD mutations, all linked to a specific pathology, are found on *MAPT*, *PGRN* and  
38  
39 *C9ORF72* genes [8].  
40

41  
42 FTD prevalence was estimated between 0.01-4.61 per 1,000 person and the incidence between 0.01-  
43  
44 2.5 per 1,000 person/year [9]. In recent dementia cohorts, FTD cases have been found to account for  
45  
46 1.6 to 7% of dementia cases [10,11]. However, those figures need to be considered with caution. First,  
47  
48 FTD is still underdiagnosed: neuropathological studies performed in communities where brain donation  
49  
50 reaches a high level of acceptance show that as much as 5-9 % of the elderly population with or without  
51  
52 cognitive impairment at death have FTD pathology [12,13]. It has been previously estimated that about  
53  
54 40% of FTD are misdiagnosed [14] and time to diagnosis is longer than for other dementias [15,16].  
55  
56 Second, with some exceptions [17], most past estimations have been done using the previous Lund and  
57  
58 Manchester [18] or Neary criteria [19]. Yet the revised clinical criteria and the addition of new syndromes  
59  
60 to the FTD spectrum outdate previous publications. Third, advances in neuropsychology, neuroimaging  
61  
62  
63  
64  
65

1 and cerebrospinal fluid (CSF) biomarkers and genetics have improved FTD diagnosis in challenging  
2 situations such as psychiatric, amnesic or late-onset presentations of the disease [20–22].  
3

4 However, beyond research purposes, whether improving FTD diagnosis at the population level would  
5 stand a cost-benefit analysis is a subject that should be addressed open-mindedly. Indeed, one could  
6 argue that differential dementia diagnosis workup is a costly venture [23] that can be questioned in the  
7 absence of disease-modifying treatments. The demonstration that FTD diagnosis is associated with  
8 different prognoses and therapeutic approaches in routine care would advocate against a symptomatic  
9 approach of dementia.  
10

11 Thus, data sharing on current FTD diagnoses and management is needed. We undertook the present  
12 study in a large regional memory clinic (MC) network to get a better overview of the incidence,  
13 characteristics and natural history of FTD syndromes defined using recent diagnostic criteria. The  
14 objectives were to study the characteristics of the FTD patients referred to the network from January  
15 2010 to December 2016, including age at onset, time to diagnosis, clinical presentations, cognitive  
16 progression and treatment.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

# Patients and methods

## *Patient selection*

Founded in 1993, the Méotis network is the first French MC network, involving 30 MCs in the French Nord and Pas-de-Calais departments, sharing data within a common patient database since 1997. Meotis database reached a caseload of over 104 000 patients in 2018, representing more than 350 000 visits [24]. In all MCs, a multidisciplinary assessment is performed by neurologists, geriatricians, psychologists, dedicated nurses and social workers; whenever necessary, patients can be assessed by psychiatrists, speech therapists and dedicated nurses. Diagnostic work-up is harmonized throughout the network, and standardized data on patient characteristics and healthcare activity are systematically collected. All harmonized data are monitored and computerized by a data manager in the tertiary-referral Memory Resources and Research Center (MRRC) of the Lille University Hospital.

We included patients that were referred for the first time to one of the network's MC from January 2010 to December 2016, and whose last clinical diagnosis during the follow-up was FTD, AD or other causes of dementia. We first extracted all dementia cases to calculate the respective proportions of AD and FTD syndromes. Then we focused on the subpopulation of AD and FTD syndromes for systematic comparisons. Since AD is the dominant cause of dementia, AD patients were chosen as a comparator. Data extraction was performed on September 2019, 33 months after the end of the inclusion period. For the few patients that received a diagnosis of bvFTD and lvFTD before the new criteria were published and were not followed up beyond 2011, we checked retrospectively that they fulfilled the revised diagnostic criteria. The bvFTD group comprised pure bvFTD [3], and a minority of patients with associated amyotrophic lateral sclerosis. The lvFTD group included a semantic and non-fluent agrammatic PPA [4] as well as rarer PPA variant such as apraxia of speech. The mFTD group comprised the PSP [25] and CBS [26] patients. Patients with overt motor neurone disease at presentation are usually not referred to our network because of a specialized regional amyotrophic lateral sclerosis care pathway.

## *Data collection*

1  
2  
3 We extracted the following data from the Méotis database: sex, age at first referral, referral delay, age  
4 at diagnosis, symptoms onset and diagnostic procedures. We collected the Mini Mental State  
5 Examination (MMSE) [27] and the short 4-item Instrumental Activities of Daily Living (IADL-4) [28] scores  
6 at first referral. In this article IADLs score was calculated by summing up the number of maintained  
7 activities (ranging from 0 (full dependence) to 4 (complete autonomy)). The referral delay was defined  
8 as the interval, expressed in months, between symptoms onset (declared by the patient and caregiver)  
9 and first referral to the network. The clinical follow up was defined as the interval, expressed in years,  
10 between the first and the last visit within the network. The survival was defined as the interval, expressed  
11 in years, between disease onset and death. Drug treatment was recorded at every visit. A patient was  
12 considered under a specific drug treatment if it was recorded at least once during follow up.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

23 Only the last clinical diagnosis was considered in this study because of its higher accuracy. The last  
24 diagnosis was the one made or kept after all diagnostic procedures and retained at follow-up. Diagnosis  
25 wandering was defined as the time from first referral to the last retained clinical diagnosis.  
26  
27  
28  
29

30 The date of death was retrieved from the National Institute of Statistics and Economic Studies (French:  
31 Institut national de la statistique et des études économiques) national death database thanks to the  
32 MatchID tool (<https://deces.matchid.io/>) on September 2020  
33  
34  
35  
36

37 The datasets considered in the current study are available from the corresponding author on reasonable  
38 request. The database was declared to the ad hoc commission (Commission Nationale Informatique et  
39 Libertés (CNIL)) protecting personal data (#2146189V1). Privacy and confidentiality rules were  
40 respected.  
41  
42  
43  
44  
45  
46

## *Statistical Analysis*

47  
48  
49  
50  
51 Quantitative variables were described by the mean and standard deviation if the distribution was normal,  
52 or by the median and interquartile range otherwise. Qualitative variables were described by the numbers  
53 and percentages of each modality.  
54  
55  
56

57 Diagnostic subtypes (bvFTD, FTD mFTD and AD) were described and compared across all parameters.  
58  
59 Quantitative variables were analyzed by an ANOVA or the Kruskal-Wallis non-parametric equivalent.  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Qualitative variables were compared by an exact Chi-square or Fisher's test (in the case of a theoretical number of cases below 5). A Bonferroni correction was applied to post-hoc comparisons of the FTD subgroups with respect to the AD group. The effect size was calculated as the standardized mean difference (for quantitative variables) and the Cramer's V coefficient (for qualitative variables). A mixed linear model analyzed the evolution of the MMSE over time. The factors introduced into the model were time, diagnosis and the interaction between diagnosis and time.

Incidence rates were calculated as the number of incident cases divided by the total number of person-years (py) for the catchment area over the 7 years. All rates were calculated using the reference population of the corresponding geographic area estimated by the French National Institute of Demographic Research (INED) on January 2015, as population at risk. Therefore, no variation was assumed during the 7 years of the study period. Age-standardized rates were calculated using the Revised European Standard Population 2013 (ESP2013). Results were presented in cases per 100,000 person-years.

Concerning mortality, median survival time after diagnosis was calculated for each diagnostic subtype, survival was estimated using the Kaplan–Meier model and the log-rank test was used to test of differences in survival curves according to diagnostic subtype. Hazard ratios (HRs) were also adjusted for age and sex using Cox regression.

The analyses were performed using SAS software (version 9.4).

# Results

## *Study population*

Data from 26,525 demented patients followed in the network and fulfilling inclusion criteria were extracted. Among them, 2,369 have first been seen at the MRRC (Lille tertiary-referral MC), and 24,156 first at one of the MCs belonging to the network.

During the 7 years of follow-up, 690 incident cases of FTD syndromes were identified, giving a crude incidence rate of 2.42 per 100,000 person-years ([Table 1](#)). The FTD incidence across age groups at diagnosis reached its peak in the 75-to-79 year-old group, with an incidence rate of 14.95 per 100,000 person-years. The age-standardized incidence rate was 2.90 per 100,000 person-years.

FTD syndromes represented 2.6% of the studied population, as compared with 71% AD ([Figure 1A](#)). Among FTD syndromes 64% were bvFTD, 17% lvFTD and 18% mFTD ([Table 2](#)). The proportion of FTD syndromes was higher in the MRRC (8.1%) than elsewhere (2.0%).

## *Characteristics of patients with FTD syndromes*

The sex ratio significantly differed between AD and FTD patients ( $p < 0.0001$ ,  $d = 0.1$ ) ([Table 2](#)). Men represented 47% of FTD and only 30% of AD patients. Patients with FTD syndromes were younger than those with AD at first referral (70.4 vs. 80.6 years,  $p < 0.0001$ ), and bvFTD patients were younger than the remaining FTD syndromes (69.4 vs. 72.3 years).

MMSE scores at first referral were higher in FTD syndromes than in AD (21.8 vs. 18.9,  $p < 0.0001$ ,  $d = 0.5$ ). Likewise, the median IADL-4 score was higher in patients with FTD syndromes compared to AD patients (3 vs 2,  $p < 0.0001$ ,  $d = 0.5$ ), favoring a more preserved autonomy in instrumental activities.

Among the FTD syndromes, a positive family history of dementia was identified in 14%, as compared with 2.3% of AD patients ( $p < 0.0001$ ,  $d = 0.1$ ). Among the 294 FTD syndromes referred to the MRRC, a genetic mutation was detected in 34% of the 99 patients in whom the genetic analysis was performed (47% in *C9orf72*, 32% in *PGRN* and 21% in *MAPT* genes). Mutations were more likely to be retrieved in bvFTD (95%) than in lvFTD (5%) or mFTD (0%). See [Table 1](#) for detailed comparisons between FTD syndromes and AD.

## *Diagnosis of FTD syndromes*

We then systematically studied the time to referral, time to diagnosis and diagnostic workup of FTD compared to AD patients. Referral delay was longer for FTD syndromes compared to AD (37.6 vs. 31.8 months,  $p < 0.0001$ ,  $d = 0.4$ ). Among the FTD syndromes, referral delay was the highest for bvFTD (40.0 vs. 33.3 months in other FTD). Diagnosis wandering was longer for FTD syndromes compared to AD (9.8 vs. 5.8 months,  $p < 0.001$ ,  $d = 0.1$ ), but similar across FTD syndromes.

As part of the standardized dementia diagnosis procedure, all of our patients performed an MRI, if not contraindicated. The diagnostic workup of FTD patients in the whole Méotix network included more often a FDG-PET and a lumbar puncture than the one of AD patients (23.2% vs 2.6% and 27.5% vs 3.96% respectively,  $p < 0.001$  and  $d = 0.2$  for both comparisons, [Table 2](#)). Brain imaging and lumbar puncture were more consistently used in Lille MMRC both for AD and FTD diagnosis (our unshown data).

Correlations between clinical diagnoses and pathology were excellent in the 15 patients of the study population who came to autopsy. Among the patients with available pathological examination, the 4 in the bvFTD group had FTLT-DTP ( $n = 3$ ) or FTLT-FUS ( $n = 1$ ) pathologies. All 5 patients in the mFTD group had PSP or CBD pathology. All 6 patients in the AD group had AD pathology +/- cerebral amyloid angiopathy or Lewy body pathology ( $n = 3$  and 2, respectively).

## *Natural history of FTD syndromes*

Cognitive progression estimated by the rate of MMSE decline was then assessed. Overall, there was no significant difference in the rate of MMSE decline between FTD syndromes and AD. Across FTD syndromes, bvFTD did not significantly differ from AD in the rate of MMSE decline per year (the slope was  $a_{bvFTD} = -2.0$  in bvFTD against  $a_{AD} = -1.8$  in AD,  $p = 0.4$ ). However, the decline was higher in lvFTD ( $a_{lvFTD} = -2.8$ ) and mFTD ( $a_{mFTD} = -2.6$ ) than in AD patients ( $p = 0.003$  and  $p = 0.02$ , respectively) ([Figure 1B](#)).

Follow-up was longer for FTD syndromes compared to AD (24.1 vs. 17.5 months,  $p < 0.0001$ ,  $d = 0.2$ ) and more specifically, bvFTD and lvFTD patients had a significantly longer follow up than AD patients.

As of September 2020, 48% of bvFTD, 53% of lvFTD, 76% of mFTD and 59.1% of AD patients had died ([Table 2](#)). The median survival time after diagnostic was 5.5 years for the entire sample and varied

1 significantly according to the diagnosis subtype (6.5 years for bvFTD, 6.1 for lvFTD, 5.5 for AD and 4.0  
2 for mFTD,  $p<0.001$ ) ([Figure 1C](#)). Age (HR [CI 95%] = 1.05 [1.05-1.06] for one year,  $p<0.001$ ) and male  
3 sex (1.73 [1.67-1.80],  $p<0.001$ ) were significantly associated with an increased risk of death. After  
4 adjustment for age and sex, mFTD were significantly associated with a lower median survival as  
5 compared to AD (2.32 [1.89-2.84],  $p<0.001$ ). There were no significant differences between AD and  
6 bvFTD (1.10 [0.96-1.26],  $p=0.179$ ) and between AD and lvFTD (1.21 [0.94-1.55],  $p=0.137$ ).  
7  
8  
9  
10  
11  
12  
13

### 14 *Treatment of FTD syndromes*

15

16  
17 There were sharp differences in the therapeutic approach between FTD syndromes and AD. FTD  
18 patients received less anticholinesterase inhibitors (AChEI) and memantine than AD patients (12.0% vs  
19 42.2%,  $p<0.0001$ ,  $d=0.1$  and 5.7% vs 21.8%,  $p<0.0001$ ,  $d=0.1$ , respectively). Conversely, FTD patients  
20 received more antidepressants (48.0% vs 27.0%,  $p<0.0001$ ), anxiolytics (33.2% vs 23.6%,  $p<0.0001$ ,  
21  $d=0.04$ ) and antipsychotics (17.5% vs 13.1%,  $p=0.003$ ,  $d=0.1$ ) than AD patients. The difference between  
22 AD and FTD stemmed mostly from the bvFTD group where antidepressants (55.2%), anxiolytics  
23 (38.3%) and antipsychotics (24.4%) were used the most ( $p<0.0001$  and  $d=0.1$  for the three comparison  
24 to AD). There was no significant difference in the use of hypnotics between groups ([Figure 2](#)).  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

# Discussion

The main findings of the present study are threefold: (1) despite new sets of criteria, diagnoses of FTD syndromes remained low in routine care in our regional memory clinic network; when diagnosed, bvFTD patients had longer referral delay and diagnostic wandering than AD patients; (2) the peak of incidence of bvFTD occurred between 75 and 79 years, clearly advocating against the conception of FTD as exclusively an early-onset dementia; (3) FTD syndromes differed from AD with regard to cognition and autonomy at baseline, cognitive decline and disease duration; (4) therapeutic strategies radically differed from the ones in AD.

## *Misconceptions about FTD lead to underdiagnosis*

In this retrospective study, we calculated an FTD age-standardized incidence rate of 2.9/100.000 py in our region. Our results stand in-between the ones of two recent studies using updated FTD criteria that found an incidence of 1.6/100.000 py in the United Kingdom (Norfolk and Cambridgeshire counties) and 3.05/100.000 py in Italy (Leccia and Brescia provinces) [17,29]. However, while we used the same European reference population as our British colleagues, Logroscino et al. used the Italian population for standardization. Standardization of their incidence rate with the same European population yields an FTD age-standardized incidence rate of 2.78/100.000 py, strikingly similar to ours (*our unshown data*).

We found that FTD syndromes represented 3% of the Méotis network caseload. Similar MC surveys in Netherlands [11] and Sweden [10] had 7% and 3.6% of FTD syndromes, respectively. However, all patients in the Dutch cohort were followed in the Alzheimer centre of the VU University Medical Center (VUmc), a tertiary centre where atypical dementias are likely to be addressed, possibly leading to an overrepresentation of FTD patients. Likewise, there was a 8.1% proportion of FTD patients in Lille tertiary centre. A recent review on the epidemiology of FTD highlighted three studies with high methodological standards [9]. In these publications using the Lund and Manchester [18] or Neary [19] criteria, FTD syndromes accounted for 1,1% [30], 3% [31] and 3.8% [32] of dementia cases, which is consistent with our findings.

In sharp contrast, consistent with the underdiagnosis of FTD, systematic neuropathology surveys show much higher figures. In UK brain banks from donors (of whom two thirds had dementia), FTD

1 represented 5.1% of diagnoses [33] and up to 9.4% of elderly people participating in a community brain  
2 donation program were found to have some FTD lesions at autopsy [13].  
3

4 The reasons for FTD underdiagnosis are manifold. First, late-onset FTD are often overlooked. FTD is  
5 historically considered as a major cause of early onset dementia [1], which probably contributes to FTD  
6 diagnosis being overlooked in late-onset dementia. Yet, in recent studies with pathological confirmation,  
7 one fourth of FTD cases had an age at onset >65 years [34]. In the recent literature, there is a trend  
8 toward an increase in the age at diagnosis of FTD syndromes, which may relate to the increasing age  
9 at dementia diagnosis in recent surveys [24]. While older studies showed an age at diagnosis of 65.9  
10 years [35], we found an age at diagnosis of 71.3 years, which compares to recent publications showing  
11 a mean age at diagnosis of 69.4 [36], 70.0 [37] or 71.3 years [29]. Interestingly, the peak of incidence  
12 occurred between 75 and 79 years in our survey as in the aforementioned Italian and English studies  
13 [17,29], reminding that FTD is not only a dementia of early onset.  
14  
15

16 Second, the positive diagnosis of bvFTD and its differentiation with primary psychiatric disorders is  
17 another diagnostic challenge [38] that is reflected by the increased time to presentation and time to  
18 diagnosis of the bvFTD variants as compared with the others [39,40]. Prolonged diagnostic wandering  
19 in bvFTD, associated in our study with an increased reliance on diagnostic biomarkers, seems to be a  
20 universal finding [15–17] and suggests that many cases could remain misdiagnosed. Future studies  
21 should focus on the exact determinants of the delay in referral and in diagnosis. Third, all the possible  
22 clinical presentations of FTD have not been thoroughly described and some are not taken into account  
23 by the available clinical criteria. The amnesic variant of FTD, in particular, is difficult to differentiate from  
24 AD [20,41] in particular in late-onset dementia [42]. Another example is the right temporal variant of FTD  
25 – although a recent publication proposing clinical criteria will contribute to fill the gap [43].  
26  
27

28 Overall, our survey confirms that FTD are still probably overlooked despite the use of novel clinical  
29 criteria and incorporation of new phenotypes. While progress has been made in the recognition of late-  
30 onset forms, differential diagnosis between FTD and AD remains a challenge, particularly in the oldest  
31 old, and bvFTD cases are probably still mistaken for primary psychiatric disorders.  
32  
33

34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57 *FTD syndromes differ with AD in baseline characteristics and natural history*  
58  
59  
60  
61  
62  
63  
64  
65

1 We found several key differences between FTD syndromes and AD at baseline. First, as we had  
2 previously shown [39], we confirmed that the MMSE score is higher in FTD. However, behaviour, social  
3 cognition and executive functions, the main domain impaired in bvFTD, are not properly assessed by  
4 the MMSE, which somewhat undermines the assumption that the general cognitive status is better  
5 preserved in FTD syndromes. The higher IADL-4 score in FTD compared to AD contrasted with past  
6 studies that retrieved either lower [44] or equal [45] autonomy. However, IADL-4 only assesses  
7 restriction in four activities (telephone, transportation, drug treatment, and finances) that are best  
8 associated with future dementia risk [28], thus preventing a direct comparison of our results with studies  
9 that employed the full ADL. The younger age and the better preservation of memory and visuo-motor  
10 functions, may explain the lesser impairment found in FTD as compared to AD. Impaired functional  
11 capacity in bvFTD is primarily due to behavioral symptoms and impaired social cognition, and the routine  
12 (although complex) instrumental activities of the IADL-4 may not be the most representative of the loss  
13 of autonomy in FTD syndromes. Among the FTD syndromes, the lvFTD patients had the most preserved  
14 autonomy, as found in previous studies [44,45].

15  
16 Although FTD syndromes as a whole had a similar rate of MMSE decline to AD, lvFTD and mFTD  
17 variants specifically showed a higher rate of MMSE decline in time. Additionally, lvFTD had a slightly  
18 lower score at baseline than the other variants. Since the MMSE relies mostly on language, aphasia  
19 have likely impacted the score in lvFTD. In recent studies, patterns of longitudinal MMSE decline across  
20 the FTD phenotypes have already been studied, and semantic dementia cases were shown to decline  
21 the most [46]. Regarding survival, we, as others [17], reported that mFTD had the more severe prognosis  
22 of FTD syndromes [17], followed by lvFTD and bvFTD. Despite similar MMSE decline rates between  
23 bvFTD and AD, mFTD patients had a significantly lower survival median.

#### 24 *Therapeutic strategies in FTD*

25  
26 The drug treatments used in FTD syndromes markedly differed from the ones used in AD. These  
27 observations should be interpreted with caution since differences may only reflect different customs,  
28 and not different responses to treatment. However, clinical guidance on the symptomatic treatment of  
29 FTD is limited [47], prompting physicians to use psychotropic drugs that may be used non-specifically

1  
2 in dementia, based on the medical needs and immediate efficacy. Hence the prescription habits in FTD  
3 may also reflect the neuropsychiatric symptoms and treatment response of FTD patients.

4 A publication from the Boxer's group showed that off-label use of AChEI and memantine in FTD was  
5 common in the US in 2010 [48]. In our region and in the 2010-2019 time span, we found that AChEI and  
6 memantine were used in only 12.0% and 5.7% of FTD syndromes, in accordance with recent data  
7 supporting lack of efficacy – or even deleterious effects in bvFTD and mFTD ([49,50], reviewed in  
8 [51,52]). The remaining prescriptions may reflect diagnostic hesitations with AD at the beginning of  
9 follow-up.

10 Antipsychotics and anxiolytics were more frequently used in FTD syndromes than in AD, and the  
11 difference with AD was driven by the bvFTD variant. Antipsychotics are prescribed to treat agitation in  
12 dementia whatever the aetiology (AD, FTD or others) [53], although their use is restricted to patients  
13 with severe symptoms (aggression, agitation, or psychosis) who fail to respond adequately to other  
14 pharmacological and nonpharmacological treatments. The use of anxiolytics and antipsychotics in  
15 38.3% and 24.4% of bvFTD patients, as opposed to 23.6% and 9.3% in AD, is thus a reflexion of the  
16 higher rate of productive behavioural symptoms (e.g. agitation, aggression, and psychosis) in this  
17 variant. However, the low rate of antipsychotics use in FTD demonstrated that physicians took into  
18 account the alerts on side effects [54,55] and increased mortality rate [56] in FTD and dementia patients  
19 treated with antipsychotics. The black box warning from the Food and Drug Administration was followed  
20 by a similar warning from the French Haute Autorité de Santé in 2009 ([https://www.has-  
21 sante.fr/jcms/c\\_885227/fr/limiter-la-prescription-de-neuroleptiques-dans-la-maladie-d-alzheimer](https://www.has-sante.fr/jcms/c_885227/fr/limiter-la-prescription-de-neuroleptiques-dans-la-maladie-d-alzheimer)) that  
22 had found a strong echo in the neurologic and geriatric communities.

23 The most remarkable difference however regarded the prescription of antidepressants, which was twice  
24 as important in bvFTD (55.2%) as in AD (27.0%). Indeed, although results are mixed, comprehensive  
25 reviews of the evidence from clinical trials favoured the use of selective serotonin reuptake inhibitors to  
26 treat behavioural symptoms [47,51,52,57]. Our team in particular demonstrated that trazodone,  
27 a serotonin antagonist and reuptake inhibitor, reduced irritability, agitation, and depressive symptoms in  
28 FTD [58]. The much better tolerance profile and apparent efficacy of serotonin-acting drugs logically  
29 imposed them as the mainstay of FTD treatment in our network.

## Strengths and limitations

This naturalistic study of a 6-year period is rooted in 23 years of data sharing and harmonization across a regionwide memory clinic network [24]. It allowed to analyse the trends of real-life FTD diagnosis and care over time. We reached a considerable number of new patients per year, equivalent to the one of nation-wide MC networks. Analyzing the characteristics of consecutive FTD patients first referred between 2010 and 2016 allowed us to focus on patients in which the diagnosis was made using the new criteria for bvFTD and lvFTD [3] and strengthened by follow-up. By considering a wide spectrum of FTD variants, we included patients that are often withdrawn from FTD cohorts.

Our survey confirmed many previously published data, which reinforces of the quality and validity of our database. We showed that approximately two thirds of FTD patients had a behavioural variant (bvFTD), and 17% had a language variant, which matches other databases [9,59,60]. We, as others, found a sex ratio of approximately 1:1 in FTD [9]. Thirty-five percent of our FTD patients had a family history of neuropsychiatric disease, in agreement with the literature [14,61]. Only our rate of mutations was lower than previously reported since a mutation was identified in *C9ORF72*, *MATP* or *GRN* in only 6% of the FTD patients that had a genetic analysis, against 10-15% in the literature [62]. Last but not least, pathological diagnoses when available matched the clinical diagnoses, confirming the high accuracy of the clinical diagnoses made in a structured regional network and confirmed by a prolonged follow-up.

Our survey has however a few limitations. First, important data are not systematically populated in our database. We still lack accurate cognitive, functional or disease-specific scales to assess disease progression. Furthermore, the mean follow-up of ~2 years precludes a comprehensive overview of FTD progression in many of our patients. We also acknowledge a selection bias due to the different networks involved in movement disorders and dementia care in our region, an issue that had been acknowledged in similar studies. Patients with overt motor neuron disease at presentation were not included because they were referred to a specialized regional care pathway rather than to memory clinics. Likewise, the PSP and CBS patients that were referred to our memory clinics were probably the ones presenting early behavioural and/or cognitive changes. Conversely, PSP and CBS with prominent motor symptoms were likely to be followed in movement disorders clinics, where secondary referral to MCs is not systematic. Still, our incidence rate compares to the ones of two regional cohorts including the full FTD spectrum [17,29].

### *Conclusion and outlook*

1  
2 Overall, our study showed that FTD syndromes have specific clinical features, different progression  
3 patterns and therapeutic strategies. Yet, even in a region with an organized memory clinic network, FTD  
4 is still overlooked and diagnosis wandering remains longer than in AD. Psychiatric, amnesic and/or late-  
5 onset presentations of FTD are particularly treacherous, and the overlap between cognitive/behavioral  
6 and motor presentations leads to an underestimation of the motoric presentations of FTD in memory  
7 clinics.  
8  
9

10  
11  
12  
13  
14 There is an obvious need of accurate FTD biomarkers to improve FTD diagnosis. Until and even after  
15 the avenue of such biomarkers, neuropsychology has and will have a role to play at a limited cost. The  
16 development of novel tests exploring new domains of social cognition beyond mentalization and emotion  
17 recognition is a steppingstone in this direction. Social cognition deficits have been found to be a reliable  
18 and effective cognitive marker of FTD, especially in patients with a psychiatric [63] or amnesic [64,65]  
19 presentations. Social cognition deficits are probably underestimated in mFTD as well [66], advocating  
20 for a more systematic assessment of social cognition in memory, geriatric, movement disorders and  
21 psychiatry clinics. In order to improve FTD diagnosis, the classical boundaries between specialties  
22 should be broken. Indeed, it is only through a harmonization in diagnostic procedures and databases  
23 involving geriatricians, movement disorders specialists, old-age psychiatrists, neuropsychologists,  
24 speech-therapists and memory clinics that the real scope of FTD will be thoroughly apprehended. The  
25 gathering of these different disciplines into consortiums such as the Centers of Excellence in  
26 Neurodegeneration (CoEN) responds to this objective.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40


41 Additionally, initiatives are needed to raise awareness on FTD in the general population. At the eve of  
42 disease-modifying therapies, misdiagnosis of FTD may already be a loss of opportunity for patients.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

# Tables and figures

Table 1. FTD incidence rates, number of cases, and number of person-years by age group

Age group at diagnosis	Number of cases	Number of person-years	Incidence (per 100,000 person-years)
0-39	2	14,854,742	0.01
40-44	3	1,922,550	0.16
45-49	8	1,842,470	0.43
50-54	25	1,862,287	1.34
55-59	61	1,796,207	3.40
60-64	95	1,703,044	5.58
65-69	123	1,490,146	8.25
70-74	110	828,709	13.27
75-79	126	842,548	14.95
80-84	92	725,613	12.68
≥85	45	676,866	6.65
<b>Total</b>	<b>690</b>	<b>28,545,202</b>	<b>2.42</b>

**Figure 1. Characteristics and progression of patients with FTD syndromes in the Méotis network (incident cases from 2010 to 2016).** A. Aetiologies of dementia in the incident cases. B. Mixed linear model of the evolution of the MMSE over time in patients with FTD syndromes and AD. C. Survival in patients with FTD syndromes and AD




AD: Alzheimer's disease, FTD: Frontotemporal dementia, bvFTD: behavioural variant of the frontotemporal dementia, lvFTD: speech variant of the frontotemporal dementia, mFTD: motor variant of the frontotemporal dementia, Other: other type of dementia due to a neurodegenerative or vascular disease

**Table 2. Demographics and clinical features of FTD syndromes**

Variable	bvFTD			lvFTD			mFTD			AD	
	N= 446			N= 118			N = 126			N = 18831	
	Value	NA	p*	Value	NA	p*	Value	NA	p*	Value	NA
Women, n (%)	232 (52.2)	0	<0.001	68 (57.6)	57.6	0,01	68 (54)	0	< 0,001	13162 (69.9)	0
Age at first visit, m (sd)	69.4 (10.3)	0	<0.001	72.7 (9.5)	0	<0.001	72.0 (8.0)	0	<0.001	80.6 (7.5)	0
Age at diagnosis, m (sd)	70.2 (10.3)	0	<0.001	73.6 (9.7)	0	<0.001	72.8 (8.1)	0	<0.001	81.0 (7.3)	0
Delay referral (months), m (sd)	40.0 (41.2)	87	<0.001	30.8 (20.5)	19	0.84	35.8 (29.9)	24	0.13	31.8 (32.0)	5370
Diagnosis wandering (months), m (sd)	9.9 (16.8)	0	<0.001	10.5 (16.4)	0	<0.001	9.1 (15.1)	0	<0.001	5.8 (14.2)	0
Clinical follow up (months), m (sd)	25.2 (24.0)	0	<0.001	24.2 (22.0)	0	<0.001	20.2 (19.6)	0	0,05	17.5 (21.4)	0
Dementia family history, n (%)	75 (16.8)	0	<0.001	11 (9.3)	0	<0.001	13 (10.3)	0	<0.001	508 (2.7)	0
MMSE at first visit, m (sd)	22.1 (6.1)	117	0,02	20.6 (7.5)	27	0.002	21.9 (6.1)	38	<0.001	18.9 (6.0)	2246
IADL-4, median	3	199	<0.001	4	38	<0.001	3	54	< 0,001	2	6689
PET in the network, n (%)	117 (26.2)	0	<0.001	18 (15.2)	0	<0.001	25 (19.8)	0	<0.001	484 (2.5)	0
CSF in the network, n (%)	135 (30.3)	0	<0.001	22 (18.6)	0	<0.001	33 (26.2)	0	<0.001	759 (3.9)	0
Death, n (%)	213 (48.4)	0		63 (53.4)	0		96 (76.2)	0		11220 (59.1)	0
Survival in years, median	6.5	0	0.18	6.1	0	0.14	4.0	0	<0.001	5.5	0
Autopsy verification, n (%)	4 (0.8)	0		0 (0)	0		5 (4.0)	0		6 (0.03)	0

AD: Alzheimer's disease, FTD: Frontotemporal dementia, bvFTD: behavioral variant of the frontotemporal dementia, IADL: Instrumental Activities of Daily Livings, lvFTD: speech variant of the frontotemporal dementia, mFTD: motor variant of the frontotemporal dementia, IADL-4 : Instrumental Activities of Daily Living – 4, MMSE: Mini Mental State Examination, m (sd) : mean (standard deviation), PET : Position Emission Tomography, CSF : CerebroSpinal Fluid. \* Comparison to AD

Figure 2. Drug treatments used in FTD syndromes compared to AD



AD: Alzheimer's disease, AChEI: anticholinesterase inhibitor, bvFTD: behavioral variant of the frontotemporal dementia, lvFTD: speech variant of the frontotemporal dementia, mFTD: motor variant of the frontotemporal dementia

# Declarations

## *Ethics approval and consent to participate*

The database was declared to the ad hoc commission (Commission Nationale Informatique et Libertés (CNIL)) protecting personal data (#2146189V1). Privacy and confidentiality rules were respected.

## *Consent for publication*

Not applicable

## *Availability of data and materials*

The datasets considered in the current study are available from the corresponding author on reasonable request.

## *Competing interests*

The authors declare that they have no competing interests.

## *Funding*

The study was partially funded by laboratory of excellence DistAlz.

## *Authors' contributions*

ML did the study concept and design, the analysis and interpretation of data, drafted the manuscript, revised the manuscript for important intellectual content, statistical analysis, administrative support. MB did the study concept and design, the interpretation of data and revised the manuscript for important intellectual content. ES did the statistical analysis and revised the manuscript for important intellectual content. EM did the analysis and interpretation of data and revised the manuscript for important intellectual content. CAB, SB, PC, YC, VD, FL, MAM, ARS, FP and the Méotis network collected the data and revised the manuscript for important intellectual content. MW did the statistical analysis of the incidence and survival. ILB performed the genetic analysis. TL did the study concept and design, the analysis and interpretation of data, drafted the manuscript, revised the manuscript for important intellectual content and supervised the overall study.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

### *Acknowledgements*

The authors thank Catherine Ficot, Nathalie Jourdan and Brigitte Leprince for their continuous energetic contribution to the network as well as the overall Méotis.

The authors also thank Antoine Lamer and the MatchID team for their help in retrieving the dates of death.

### *Authors' information (optional)*

Not applicable

# References

1. Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. *Neurology*. 2002;58:1615–21.
2. Lashley T, Rohrer JD, Mead S, Revesz T. Review: an update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. *Neuropathology and Applied Neurobiology*. 2015;41:858–81.
3. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain*. 2011;134:2456–77.
4. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. *Neurology*. 2011;76:1006–14.
5. Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. *Movement disorders : official journal of the Movement Disorder Society*. 2017;32:853–64.
6. Josephs KA, Hodges JR, Snowden JS, Mackenzie IR, Neumann M, Mann DM, et al. Neuropathological background of phenotypical variability in frontotemporal dementia. *Acta neuropathologica*. 2011;122:137–53.
7. Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG. The evolution and pathology of frontotemporal dementia. *Brain*. 2005;128:1996–2005.
8. Greaves CV, Rohrer JD. An update on genetic frontotemporal dementia. *Journal of Neurology*. 2019;266:2075–86.
9. Hogan DB, Jetté N, Fiest KM, Roberts JI, Pearson D, Smith EE, et al. The Prevalence and Incidence of Frontotemporal Dementia: a Systematic Review. *The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques*. 2016;43 Suppl 1:S96–109.
10. Religa D, Fereshtehnejad S-M, Cermakova P, Edlund A-K, Garcia-Ptacek S, Granqvist N, et al. SveDem, the Swedish Dementia Registry - a tool for improving the quality of diagnostics, treatment and care of dementia patients in clinical practice. *PloS one*. 2015;10:e0116538.
11. Van der Flier WM, Scheltens P. Amsterdam Dementia Cohort: Performing Research to Optimize Care. *J Alzheimer's Dis*. 2018;62:1091–111.
12. Barker WW, Luis CA, Kashuba A, Luis M, Harwood DG, Loewenstein D, et al. Relative Frequencies of Alzheimer Disease, Lewy Body, Vascular and Frontotemporal Dementia, and

1 Hippocampal Sclerosis in the State of Florida Brain Bank. *Alz Dis Assoc Dis.* 2002;16:203–  
2 12.

3 13. Beach TG, Adler CH, Sue LI, Serrano G, Shill HA, Walker DG, et al. Arizona Study of  
4 Aging and Neurodegenerative Disorders and Brain and Body Donation Program.  
5 *Neuropathology.* 2015;35:354–89.  
6

7  
8 14. Rosso SM, Kaat LD, Baks T, Joosse M, Koning I de, Pijnenburg Y, et al. Frontotemporal  
9 dementia in The Netherlands: patient characteristics and prevalence estimates from a  
10 population-based study. *Brain.* 2003;126:2016–22.  
11

12  
13 15. Van de Vliet D, Vugt ME de, Bakker C, Pijnenburg YAL, Vernooij-Dassen MJFJ,  
14 Koopmans RTCM, et al. Time to diagnosis in young-onset dementia as compared with late-  
15 onset dementia. *Psychol Med.* 2013;43:423–32.  
16

17  
18 16. Zhao M, Lv X, Tuerxun M, He J, Luo B, Chen W, et al. Delayed help seeking behavior in  
19 dementia care: preliminary findings from the Clinical Pathway for Alzheimer’s Disease in  
20 China (CPAD) study. *Int Psychogeriatr.* 2015;28:211–9.  
21

22  
23 17. Coyle-Gilchrist ITS, Dick KM, Patterson K, Rodríguez PV, Wehmann E, Wilcox A, et al.  
24 Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes.  
25 *Neurology.* 2016;86:1736–43.  
26

27  
28 18. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and  
29 Manchester Groups. *J Neurology Neurosurg Psychiatry.* 1994;57:416.  
30

31  
32 19. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal  
33 lobar degeneration. *Neurology.* 1998;51:1546–54.  
34

35  
36 20. Bertoux M, Souza LC de, Corlier F, Lamari F, Bottlaender M, Dubois B, et al. Two  
37 distinct amnesic profiles in behavioral variant frontotemporal dementia. *Biological*  
38 *psychiatry.* 2014;75:582–8.  
39

40  
41 21. Ducharme S, Price BH, Larvie M, Dougherty DD, Dickerson BC. Clinical Approach to  
42 the Differential Diagnosis Between Behavioral Variant Frontotemporal Dementia and  
43 Primary Psychiatric Disorders. *The American journal of psychiatry.* 2015;172:827–37.  
44

45  
46 22. Jack CR, Knopman DS, Chételat G, Dickson D, Fagan AM, Frisoni GB, et al. Suspected  
47 non-Alzheimer disease pathophysiology--concept and controversy. *Nature Reviews*  
48 *Neurology.* 2016;12:117–24.  
49

50  
51 23. Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, et al. Defeating  
52 Alzheimer’s disease and other dementias: a priority for European science and society. *Lancet*  
53 *Neurology.* 2016;15:455–532.  
54

55  
56 24. Chen Y, Lebouvier T, Skrobala E, Volpe- Gillot L, Huvent- Grelle D, Jourdan N, et al.  
57 Twenty- year trends in patient referrals throughout the creation and development of a  
58 regional memory clinic network. *Alzheimer’s Dementia Transl Res Clin Interventions.*  
59 2020;6.  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
25. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP International Workshop. *Neurology*. 1996;47:1–9.
  26. Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al. Criteria for the diagnosis of corticobasal degeneration. *Neurology*. 2013;80:496–503.
  27. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. *Journal of psychiatric research*. 1975;12:189–98.
  28. Pérès K, Helmer C, Amieva H, Orgogozo J-M, Rouch I, Dartigues J-F, et al. Natural history of decline in instrumental activities of daily living performance over the 10 years preceding the clinical diagnosis of dementia: a prospective population-based study. *Journal of the American Geriatrics Society*. 2008;56:37–44.
  29. Logroscino G, Piccininni M, Binetti G, Zecca C, Turrone R, Capozzo R, et al. Incidence of frontotemporal lobar degeneration in Italy: The Salento-Brescia Registry study. *Neurology*. 2019;92:e2355–63.
  30. Gurvit H, Emre M, Tinaz S, Bilgic B, Hanagasi H, Sahin H, et al. The prevalence of dementia in an urban Turkish population. *Am J Alzheimer’s Dis Other Dementias*. 2008;23:67–76.
  31. Gascón-Bayarri J, Reñé R, Barrio JLD, Pedro-Cuesta JD, Ramón JM, Manubens JM, et al. Prevalence of Dementia Subtypes in El Prat de Llobregat, Catalonia, Spain: The PRATICON Study. *Neuroepidemiology*. 2007;28:224–34.
  32. Andreasen N, Blennow K, Sjödin C, Winblad B, Svärdsudd K. Prevalence and Incidence of Clinically Diagnosed Memory Impairments in a Geographically Defined General Population in Sweden. *Neuroepidemiology*. 1999;18:144–55.
  33. Francis PT, Costello H, Hayes GM. Brains for Dementia Research: Evolution in a Longitudinal Brain Donation Cohort to Maximize Current and Future Value. *J Alzheimer’s Dis*. 2018;Preprint:1–10.
  34. Seo SW, Thibodeau M-P, Perry DC, Hua A, Sidhu M, Sible I, et al. Early vs late age at onset frontotemporal dementia and frontotemporal lobar degeneration. *Neurology*. 2018;90:e1047–56.
  35. Borroni B, Agosti C, Bellelli G, Padovani A. Is early-onset clinically different from late-onset frontotemporal dementia? *Eur J Neurol*. 2008;15:1412–5.
  36. Nilsson C, Waldö ML, Nilsson K, Santillo A, Vestberg S. Age-related incidence and family history in frontotemporal dementia: data from the Swedish Dementia Registry. *PLoS one*. 2014;9:e94901.
  37. Turcano P, Stang CD, Mielke MM, Martin PR, Upadhyaya SG, Josephs KA, et al. Incidence of frontotemporal disorders in Olmsted County: A population-based study. *Alzheimer’s Dementia J Alzheimer’s Assoc*. 2019;

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
38. Ducharme S, Dols A, Laforce R, Devenney E, Kumfor F, Stock J van den, et al. Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. *Brain J Neurology*. 2020;
  39. Pasquier F, Richard F, Lebert F. Natural history of frontotemporal dementia: comparison with Alzheimer's disease. *Dementia and geriatric cognitive disorders*. 2004;17:253–7.
  40. Woolley JD, Khan BK, Murthy NK, Miller BL, Rankin KP. The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. *J Clin Psychiatry*. 2011;72:126–33.
  41. Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. *Brain : a journal of neurology*. 2019;
  42. Bertoux M, Cassagnaud P, Lebouvier T, Lebert F, Sarazin M, Ber IL, et al. Does amnesia specifically predict Alzheimer's pathology? A neuropathological study. *Neurobiol Aging*. 2020;
  43. **Ulugut Erkoyun H**, Groot C, Heilbron R, Nelissen A, Rossum J van, Jutten R, et al. A clinical-radiological framework of the right temporal variant of frontotemporal dementia. *Brain*. 2020;
  44. Mioshi E, Hodges JR. Rate of change of functional abilities in frontotemporal dementia. *Dement Geriatr Cogn*. 2009;28:419–26.
  45. Larner AJ, Hancock P. Re: Activities of daily living in frontotemporal dementia and Alzheimer disease. *Neurology*. 2008;70:658.
  46. Tan KS, Libon DJ, Rascovsky K, Grossman M, Xie SX. Differential longitudinal decline on the Mini-Mental State Examination in frontotemporal lobar degeneration and Alzheimer disease. *Alzheimer disease and associated disorders*. 2013;27:310–5.
  47. Trieu C, Gossink F, Stek ML, Scheltens P, Pijnenburg YAL, Dols A. Effectiveness of Pharmacological Interventions for Symptoms of Behavioral Variant Frontotemporal Dementia: A Systematic Review. *Cognitive Behav Neurology Official J Soc Behav Cognitive Neurology*. 2020;33:1–15.
  48. Hu B, Ross L, Neuhaus J, Knopman D, Kramer J, Boeve B, et al. Off-label medication use in frontotemporal dementia. *Am J Alzheimer's Dis Other Dementias*. 2010;25:128–33.
  49. Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary Findings: Behavioral Worsening on Donepezil in Patients With Frontotemporal Dementia. *Am J Geriatric Psychiatry*. 2012;15:84–7.
  50. Vercelletto M, Boutoleau-Brettonnière C, Volteau C, Puel M, Auriacombe S, Sarazin M, et al. Memantine in behavioral variant frontotemporal dementia: negative results. *J Alzheimer's Dis Jad*. 2011;23:749–59.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
51. Tsai RM, Boxer AL. Treatment of Frontotemporal Dementia. *Current Treatment Options in Neurology*. 2014;16:841–15.
  52. Tsai RM, Boxer AL. Therapy and clinical trials in frontotemporal dementia: past, present, and future. *Journal of neurochemistry*. 2016;138 Suppl 1:211–21.
  53. Ringman JM, Schneider L. Treatment Options for Agitation in Dementia. *Curr Treat Option Ne*. 2019;21:30.
  54. Kerssens CJ, Kerssens CJ, Pijnenburg YAL. Vulnerability to neuroleptic side effects in frontotemporal dementia. *Eur J Neurol*. 2008;15:111–2.
  55. Pijnenburg YAL, Sampson EL, Harvey RJ, Fox NC, Rossor MN. Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. *Int J Geriatr Psych*. 2002;18:67–72.
  56. Gill SS, Anderson GM, Fischer HD, Bell CM, Li P, Normand S-LT, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. *Archives of internal medicine*. 2009;169:867–73.
  57. Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. *Neurology*. 2006;66:17–22.
  58. Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. *Dementia and geriatric cognitive disorders*. 2004;17:355–9.
  59. Johnson JK, Diehl J, Mendez MF, Neuhaus J, Shapira JS, Forman M, et al. Frontotemporal Lobar Degeneration: Demographic Characteristics of 353 Patients. *Arch Neurol-chicago*. 2005;62:925–30.
  60. Ioannidis P, Konstantinopoulou E, Maiovis P, Karacostas D. The frontotemporal dementias in a tertiary referral center: classification and demographic characteristics in a series of 232 cases. *J Neurol Sci*. 2012;318:171–3.
  61. Goldman JS, Farmer JM, Wood EM, Johnson JK, Boxer A, Neuhaus J, et al. Comparison of family histories in FTLN subtypes and related tauopathies. *Neurology*. 2005;65:1817–9.
  62. Sellami L, Saracino D, Ber IL. Genetic forms of frontotemporal lobar degeneration: Current diagnostic approach and new directions in therapeutic strategies. *Rev Neurol*. 2020;
  63. Bertoux M, Delavest M, Souza LC de, Funkiewiez A, Lépine J-P, Fossati P, et al. Social Cognition and Emotional Assessment differentiates frontotemporal dementia from depression. *J Neurology Neurosurg Psychiatry*. 2012;83:411.
  64. Bertoux M, Funkiewiez A, O’Callaghan C, Dubois B, Hornberger M. Sensitivity and specificity of ventromedial prefrontal cortex tests in behavioral variant frontotemporal dementia. *Alzheimer’s Dementia*. 2013;9:S84–94.

1 65. Bertoux M, Ramanan S, Slachevsky A, Wong S, Henriquez F, Musa G, et al. So Close  
2 Yet So Far: Executive Contribution to Memory Processing in Behavioral Variant  
3 Frontotemporal Dementia. *J Alzheimer's Dis.* 2016;54:1005–14.  
4

5 66. Ghosh BCP, Calder AJ, Peers PV, Lawrence AD, Acosta-Cabronero J, Pereira JM, et al.  
6 Social cognitive deficits and their neural correlates in progressive supranuclear palsy. *Brain.*  
7 2012;135:2089–102.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65